1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

09 Apr 2024
Admin
News Article

ErlySign Gets CDSCO Nod for Trials for Oral Cancer Detection Technology

ErlySign gets CDSCO nod for large-scale clinical trials for oral cancer detection technology

Overview

ErlySign, a Nagpur-based biotech start-up received the approval from the Central Drugs Standard Control Organization (CDSCO) for its active salivary biomarker study designed for early cancer detection.

Approval for Large-Scale Trial

Following a comprehensive year-long investigation and based on in-house validation data of 150 test samples, the Indian Regulatory Authority CDSCO has granted permission to ErlySign to proceed with large-scale clinical trials.
Notably, during the initial studies, ErlySign's active salivary biomarker study showcased remarkable performance, demonstrating a sensitivity of 98% and an unparalleled specificity of 100%.

Revolutionizing Technology

The proprietary technology developed by ErlySign promises to revolutionise cancer detection through its advanced approach.
The company has also launched an automated multi-sample reader for its oral cancer detection kit.
This streamlines the testing process, allowing multiple tests to be processed within a mere 15-20 minutes.

Words from CEO: ErlySign

"Our mission is to provide an easy, accurate, affordable, and painless solution for early cancer detection. The active salivary biomarker study, now approved by CDSCO, marks a significant step towards achieving this goal. With our technology, individuals can now detect precancerous conditions even before the appearance of any oral lesion or tumour formation, empowering proactive intervention and potentially saving countless lives,” stated Shubhendra Singh Thakur, CEO, ErlySign.

Oral Cancer Detection Kit

The company said that its oral cancer detection kit offers a semi-quantitative approach, allowing for the assessment of pre-cancerous conditions through saliva biomarkers.
Results are provided as low, moderate, or high risk, providing individuals with actionable insights into their cancer risk profile.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!